Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England

References

• McLean S, Hoogendoorn M, Hoogenveen RT, et al. Projecting the COPD population and costs in England and Scotland: 2011 to 2030. Sci Rep. 2016;6(1):1–10. doi:10.1038/srep31893
   PubMedGoogle Scholar
• Trueman D, Woodcock F, Hancock E; British Lung Foundation. Estimating the economic burden of respiratory illness in the UK; 2017. Available from: http://allcatsrgrey.org.uk/wp/wpfb-file/pc-1601_-_economic_burden_report_final_8cdaba2a-589a-4a49-bd14-f45d66167795-pdf/. Accessed March 30, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed January 4, 2021.
   Google Scholar
• National Health Services Digital. Hospital admitted patient care activity 2019-20: diagnosis; 2020. Available from: https://files.digital.nhs.uk/37/8D9781/hosp-epis-stat-admi-diag-2019-20-tab%20supp.xlsx. Accessed January 4, 2021.
   Google Scholar
• NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018. Available from: https://www.nice.org.uk/guidance/ng115. Accessed September 9, 2020.
   Google Scholar
• European Medicines Agency. Trelegy Ellipta - summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/trelegy-ellipta-epar-product-information_en.pdf. Accessed January 4, 2021.
   Google Scholar
• European Medicines Agency. Trimbow - summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/trimbow-epar-product-information_en.pdf. Accessed January 4, 2021.
   Google Scholar
• European Medicines Agency. Trixeo Aerosphere - summary of product characteristics; 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf. Accessed January 4, 2021.
   Google Scholar
• Gruffydd-Jones K, Brusselle G, Jones R, et al. Erratum: changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study. NPJ Prim Care Respir Med. 2017;27:17004.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Poole C, Webster S, Tebboth A, Dickinson S, Gayle A. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respir Res. 2018;19(1):63.
   PubMedGoogle Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750
   PubMed Web of Science ®Google Scholar
• Bogart M, Glassberg MB, Reinsch T, Stanford RH. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respir Med. 2018;145:138–144. doi:10.1016/j.rmed.2018.10.013
   PubMed Web of Science ®Google Scholar
• Mainar AS, Huerta A, Artieda RN, Monsó E, Landis SH, Ismaila AS. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:2121. doi:10.2147/COPD.S211854
   PubMed Web of Science ®Google Scholar
• Medicines & Healthcare Products Regulatory Agency. Release notes: CPRD GOLD November 2020; 2020. Available from: https://www.cprd.com/data-highlights. Accessed December 1, 2020.
   Google Scholar
• CPRD-GOLD. Primary care data for public health research; 2021. Available from: https://cprd.com/primary-care. Accessed September 8, 2020.
   Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• NHS Digital. Hospital Episode Statistics (HES); 2019. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. Accessed May 27, 2020.
   Google Scholar
• PSSRU. Personal Social Service Research Unit - unit costs of health and social care; 2018. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/#sections. Accessed January 4, 2021.
   Google Scholar
• NHS prescription services. NHS prescription cost analysis; 2017. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-cost-analysis-england-2016. Accessed January 4, 2021.
   Google Scholar
• NHS HRG4+. NHS HRG4+, local payment grouper; 2018. Available from: https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-tools/payment-hrg4-2017-18-local-payment-grouper. Accessed January 4, 2021.
   Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS One. 2016;11(3):e0151357. doi:10.1371/journal.pone.0151357
   PubMed Web of Science ®Google Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65.
   PubMed Web of Science ®Google Scholar
• Tavares R, Zhang W, Dang-Tan T, et al. The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD. Eur Respir J. 2016;48:PA300.
   Web of Science ®Google Scholar
• Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012;141(1):81–86.
   PubMed Web of Science ®Google Scholar
• Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther. 2008;30:1003–1016.
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647.
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–223.
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial. Respir Med. 2017;131:27–34.
   PubMed Web of Science ®Google Scholar
• Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9(9):e105296.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681.
   PubMed Web of Science ®Google Scholar